16 September 2026 editorial review · Trial
Allogenic islet cell transplantation at University of Chicago: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the trial evidence page →Baseline trial evidence review: A–H
Outcome: Expanded sparse summary/eligibility using current registry design, inclusion criteria and primary outcome; no efficacy inferred from registration.
Registry: NCT00160732. Registered endpoint checked: decrease in insulin requirement - Subjects able to maintain fasting blood glucose concentrations below 126 mg/dL and 2-hour post prandial levels below 180 mg/dL will be considered to be insulin independent. (Monthly); decrease in incidence of hypoglycemic events (Monthly). Eligibility check: Registry age 18 Years to 58 Years; substantive diagnosis/stage, device and other inclusion restrictions were compared with the public eligibility summary. The registry remains the source for full exclusions. Limits: No usable primary abstract was independently recovered in this pass for this record. Protocol/design wording was assessed; any existing detailed sponsor, conference or historical outcome claims require their cited source and were not independently certified through full-text review.